MontoriVMPermanyer-MiraldaGFerreira-GonzalezI. Validity of composite end points in clinical trials. BMJ2005;330:594–6.
2.
SchulzKFGrimesDA. Multiplicity in randomized trials I: endpoints and treatments. Lancet2005;365:1591–5.
3.
CookDIGebskiVJKeechAC. Subgroup analysis in clinical trials. Med J Aust2004;180:289–91.
4.
FreemantleNCalvertMWoodJ. Composite outcomes in randomized trials: greater precision but with greater uncertainty?JAMA2003;289:2554–9.
5.
YusufSPfefferMASwedbergK. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362:777–81.
6.
NiewoehnerDEErblandMLDeupreeRR. Effect of systematic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med1999;340:1941–7.
7.
CrowtherCAHillerJEMossJR. Australian Carbohydrate Intolerance Study in Pregnant Women (AHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med2005;352:2477–86.
8.
LewisEJHunsickerLGClarkeWR. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851–60.
9.
CourtneyCFarrellDGrayR. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet2004;363:2105–15.
10.
MontoriVMBusseJWPermanyer-MiraldaG. How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: should I dump this lump?ACP J Club2005;143:A8.
